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Abstract

Respiratory distress syndrome (RDS) is a common consequence of pulmonary
immaturity in the lungs of neonates. RDS is the result of the deficient secretion of
endogenous surfactant, causing increased surface tension in the alveolar sacs leading to
respiratory compromise. RDS is more common in the preterm neonate but can be
experienced by neonates at any gestational age. Treatment for RDS formerly consisted of
mechanical ventilation and oxygen therapy to treat and relieve symptoms but not the
cause. A new treatment method, developed largely in the 1980s and 90s is the use of
exogenous surfactant to treat the deficiency exhibited in RDS. The administration of
exogenous (natural or artificial) surfactant has been shown to greatly decrease the rate of
respiratory failure in neonates experiencing respiratory distress and has greatly increased
their survival rate. The current use of exogenous surfactant in neonates with RDS has
greatly reduced the morbidity and mortality rates of neonates suffering from this disease.
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The Utilization of Exogenous Surfactant in the Neonate
Respiratory distress syndrome (RDS) is a disease observed in neonates that is
caused to pulmonary immaturity. It is caused by the lack of an endogenous substance,
called surfactant, normally produced by the lungs. This substance is responsible for
facilitating and maintaining inflation of the lower airways and diffusion of oxygen into
the pulmonary capillaries. Without it, breathing is nearly impossible and symptoms such
as accessory muscle use, cyanosis, and tachypnea ensue rapidly after birth. Former
treatment methods consisted mostly of the use of mechanical ventilation and oxygen
therapy; today however, treatment involves the administration of an exogenous form of
surfactant. The development of exogenous surfactant therapy has decreased the
morbidity and mortality rates of neonates with RDS immensely; because of its institution
in most neonatal care environments, RDS is rarely manifested in otherwise healthy
neonates beyond their first few hours of life (Wrobel, 2004).
Hyaline Membrane Disease
In the early 1950-1960s, a respiratory disorder, hyaline membrane disease, was
affecting tens of thousands of premature and full term neonates each year. With its
pathophysiology not yet fully understood by clinicians, treatment options were minimal
and nonspecific. The most prominent victim of this disease was the son of President John
F. Kennedy and First Lady Jacquelyn Kennedy who expired two days after he was born
five and a half weeks prematurely (Wrobel, 2004). It was at this time that physicians and
scientists started working together to uncover the mystery of this unidentified neonatal
killer.
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Respiratory Distress Syndrome
Discovery of the Disease
The disease formerly known as hyaline membrane disease is now commonly
referred to as RDS. The original name of this mysterious disease was derived from the
hyaline membranes found at autopsy in the lungs of neonates whose cause of death was
unknown. Most physicians believed these membranes were the culprits of many
premature infant deaths. However, their origin was unclear. Some speculated that the
membranes were formed from neonates aspirating amniotic fluid or milk. Regardless of
how they formed or where they came from, it was believed that the membranes
themselves impeded airflow, causing the symptoms observed in many neonates,
including circumoral cyanosis, dyspnea, retractions, and grunting (Wrobel, 2004).
One of the major turning points in the investigation of this neonatal disease was
when pathology studies revealed the presence of fibrinogen, a protein normally found in
the blood, composed among the hyaline membranes. This revealed that the membranes
must have formed within the infant’s own body, rather than an extrinsic source. This
discovery shifted the research focus to the internal composition of the neonatal
respiratory tract. Another advancement was made in the study of this disease when
researchers found that only infants who had taken at least a few breaths displayed these
hyaline membranes, and such structures were never observed in the lungs of stillborn
infants. This suggested that the membranes were formed endogenously in the lungs as a
result of lung injury rather than the cause of injury (Wrobel, 2004).
Dr. Mary Ellen Avery, a pediatric resident at Johns Hopkins in the mid-1950s,
was a pioneer of research on hyaline membrane disease. She had observed many
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neonates experience the same struggle to breathe and wondered what was really causing
this terrible disease. One discovery she uncovered was that unlike babies who died of
other causes, those who died of hyaline membrane disease had no residual air in their
lungs at autopsy (Wrobel, 2004). Dr. Avery found it hard to understand this finding
because it did not make sense that these babies whom she watched struggle for breath
seemed to be unable to retain air.
This question ultimately led Dr. Avery and her colleague Dr. Jere Mead to
discover the mechanism underlying the inability of these premature infant lungs to
expand and retain air. An earlier discovery by physiologist John Clements of a substance
called surfactant led Avery and Mead to conclude that hyaline membrane disease was not
caused by the presence of something foreign but rather the absence of something
intrinsic: endogenous surfactant (Wrobel, 2004). Surfactant lines the alveoli in the lungs,
which are the small air sacs responsible for perfusion and oxygen delivery to the blood
(Davidson, London, & Ladewig, 2012). The discovery of surfactant explained why the
disease primarily affected premature neonates, whose lungs were not yet able to produce
surfactant, as sufficiently as full-term neonates. It also explained why not only breathing
in required extra effort, but expiration did as well, leading to the infant’s inability to
retain air. Without this substance, the surface tension of the alveoli was too high, making
the air spaces too unstable, causing their collapse. This major discovery on the cause of
respiratory distress exhibited in neonates led to a shift in research and treatment options,
ultimately leading to the production and utilization of exogenous surfactant as the
primary method of treatment.
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Normal Neonatal Pulmonary and Surfactant Development
A pregnancy is considered to be full term at 40 weeks gestation. Infants born
before 37 completed weeks are considered preterm. Preterm infants are at a higher risk
for certain problems of immaturity, including RDS, low birth weight, jaundice,
retinopathy of prematurity, and heart murmurs among other disorders related to
underdevelopment. The first few hours of life, known as the neonatal transition period, is
a critical time for the identification and treatment of various cardiovascular and
respiratory abnormalities, where rapid intervention may be necessary. During the
newborn period, which is the time from birth through the twenty-eighth day of life, the
newborn undergoes numerous physiologic adaptations in order to make the successful
transition from intrauterine to extrauterine life. One of the major adaptations a newborn
must undergo is an adaptation of the respiratory system (Davidson et al., 2012).
The respiratory system is composed of an upper and lower respiratory tract. The
upper airway consists of the nose, mouth, pharynx, epiglottis, larynx, and trachea and
facilitates airflow. When air enters the respiratory tract through the nose, it is warmed,
moistened, and filtered by the nasal mucosa. From there it enters the pharynx, located in
the back of the mouth, commonly called the throat. The pharynx terminates at the
epiglottis, which protects the entrance to the larynx leading to the trachea. The epiglottis
covers the larynx during swallowing to prevent aspiration and opens to allow the passage
of air. Beyond the trachea is the beginning of the lower respiratory tract, which consists
of the bronchi, bronchioles, alveolar ducts, and alveoli. The lower respiratory tract is
responsible for perfusion. The lower airway, with the exception of the bronchi, is located
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entirely inside the lung tissue. The main stem bronchi subdivide into smaller
bronchioles, leading to the alveolar ducts and terminating at the alveoli.
The alveoli are small grape-like clusters of air sacs, which are the primary site of
gas exchange (Grossman, 2014). Gas exchange occurs at the alveolar-capillary
membrane where the alveoli are in contact with pulmonary capillaries and transfer
oxygen and carbon dioxide by diffusion across the membrane. Alveoli have the natural
tendency to collapse, as they are very unstable. In order to keep these tiny air sacs open,
the alveoli secret the lipoprotein surfactant to create the necessary surface tension to keep
the alveoli patent (Eisel, 2014). Figure 1 below illustrates the human respiratory anatomy.
Figure 1. The Human Respiratory Anatomy

Figure 1. Depicts the anatomy of the upper and lower airways. Adapted from
“Bubbles, Babies, and Biology: The Story of Surfactant,” by S, Wrobel, 2004, The
Federation of American Societies of Experimental Biology Journal, 18, p. 1625.
Copied by permission from the Federation of American Societies of Experimental
Biology. Copyright 2016.
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When a newborn begins his or her life as a separate being, he or she must
immediately adapt to the extrauterine world by establishing respiratory function and
ventilation. This transition involves radical and rapid physiologic change. However,
even before these significant events occur at birth, adequate lung development depends
on vital intrauterine factors. During the first 20 weeks of gestation, lung development
primarily involves differentiation of pulmonary, vascular, and lymphatic structures
beginning with the formation of the trachea, bronchi, and lung buds at six weeks
gestation. By seven weeks, the diaphragm begins to form and separate the thoracic and
abdominal cavities. A definite shape of the lungs is observable by the twelfth week of
pregnancy. Before birth the fetus practices breathing movements that aid in the
development of lung tissue and strengthen respiratory muscles. These movements may
begin around the seventeenth week of pregnancy and continue throughout the pregnancy.
These breathing movements facilitate the regulation of lung fluid volume and lung
growth. At 24 weeks, the nostrils reopen and the alveoli appear in the lungs and begin
producing surfactant. At 38 weeks, the lecithin-sphingomyelin ratio, which is a
component of surfactant, approaches 2:1, indicating that surfactant production is
sufficient (Davidson et al., 2012).
Alveolar duct formation begins at 20-24 weeks gestation, followed by the
formation of primary alveoli at 24-28 weeks. Initially, these alveolar cells begin to
differentiate into type I cells necessary for gas exchange and type II cells that provide for
the synthesis and storage of surfactant (Martin, 2015). Surfactant is critical for proper
alveolar expansion and functioning. It is composed of surface-active phospholipids,
lecithin and sphingomyelin, which help keep the alveolar air sacs open during gas
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exchange (Davidson et al., 2012). Type II cells begin to increase further between 28-30
weeks gestation, as surfactant is produced within them. Surfactant production peaks at
around 38 weeks gestation and continues to be produced until the pregnancy reaches fullterm. This is a crucial time when preterm neonates born without sufficient amounts of
surfactant exhibit RDS symptoms as a result. Surfactant reduces alveolar surface tension,
making it possible for the alveoli to expand and preventing the likelihood of alveolar
collapse. Without surfactant, the air spaces are unstable and ineffective at facilitating
proper airflow and oxygen uptake. Preterm infants may also have increased respiratory
fluid in the alveolar spaces, making effective gas exchange difficult (Martin, 2014a).
The physiology of respiration is broken down into three phases: inspiration,
expiration, and respiration. Inspiration is achieved through ventilation, the movement of
air into the lungs, while expiration is the opposite, moving air out of the lungs (Eisel,
2014). Inspiration and expiration are accomplished through intrathoracic pressure
changes in response to the pressure at the airway opening. Contraction of the diaphragm
and intercostal muscles works to decrease intrathoracic pressure, preparing for lung
expansion. Naturally, gas flows from an area of higher pressure, in this case the
atmospheric pressure outside of the body to an area of low pressure, the intrathoracic
space. The process of inspiration takes a higher amount of effort from the body; whereas,
expiration is a relatively passive response. The amount of air taken in is determined by
the individual’s tidal volume (VT), volume of air exchanged with each breath (Eisel,
2014). A normal VT for an adult is about 500mL; for a neonate it is much smaller,
measured around 5mL/kg (Alapont, Villanueva, & Benavente, 2014). When this amount
of air is inhaled, it moves through the bronchioles and terminates at the alveoli, which is
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the primary site of gas exchange in the lungs. As previously mentioned, alveoli are very
unstable and have the tendency to collapse. To facilitate their expansion, the alveoli
secrete surfactant, a lipoprotein that lowers the surface tension, thus reducing the amount
of pressure needed to inflate, making them less likely to collapse (Eisel, 2014).
Respiration occurs at the alveolar-capillary membrane (ACM) by a process called
diffusion. Diffusion during respiration involves the movement of oxygen and carbon
dioxide from an area of higher concentration to an area of lower concentration.
Therefore, oxygen moves from the atmosphere air in the alveolar sacs where its
concentration is higher, across the ACM and into the pulmonary capillaries where its
concentration is lower. At the same time, carbon dioxide diffuses from the pulmonary
capillaries across the ACM into the alveoli where it is then expired into the atmosphere
during exhalation (Eisel, 2014). The oxygen is then carried by arterial blood back to the
heart and pumped throughout the body. The partial pressure of oxygen (PaO2) in arterial
blood, and SaO2, the amount of oxygen bound to hemoglobin, measure the oxygenation
of the blood. These values are measured by pulse oximetry and arterial blood gases,
which give a better clinical picture of the efficiency of gas, transfer in the lungs and
overall tissue oxygenation.
The lungs have a capacity of elastic recoil due to the elastin fibers found in the
alveolar walls, bronchioles, and chest wall. This elastic recoil gives lungs the tendency to
relax after being expanded during inspiration, allowing a passive decrease in volume
caused by increased intrathoracic pressure (Eisel, 2014). The ease of lung elasticity
while expanding and relaxing is driven by compliance, the distensibility of the lungs.
When compliance is decreased, it is harder for the lungs to inflate, making inspiration
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challenging. Conditions that decrease the compliance of the lungs include those that
increase fluid in the lungs such as pneumonia and atelectasis and conditions that make
lung tissue less elastic such as pulmonary fibrosis (Eisel, 2014). Conversely, compliance
is increased when alveolar walls are damaged or when elasticity is lost, as in chronic
obstructive pulmonary disease (Kaufman, 2014).
Surfactant Deficiency
Another major detriment to respiration is surfactant deficiency. As stated above,
surfactant is a lipoprotein produced and secreted by the alveoli to facilitate their
expansion during gas exchange. LaPlace’s law describes the relationship between
inspiratory pressures and surface tension of the alveoli relative to the amount of the
alveolar volume. According to LaPlace’s law, the pressure (P) needed to keep the alveoli
open is proportional to the surface tension (T) and inversely proportional to the radius of
the alveolar volume. It is represented by the formula, P=2T/R. Therefore, if the surface
area is high and the alveolar volume is small as in end-expiration, the pressure required to
keep the alveolus open is high (Martin, 2014b). If this high pressure cannot be reached,
the alveolus collapses on itself and diffuse atelectasis occurs throughout the lung as more
and more alveoli collapse occurs. Atelectasis leads to decreased lung compliance and
hypoxemia. Pulmonary surfactant is the key to reducing the surface tension of the
alveoli, and even at low volumes it can lead to a decrease in required pressure and
maintain alveolar volume and stability (Martin, 2014b). Figure 2 depicts the effect of
surfactant and LaPlace’s law on the alveolus.
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Figure 2. The Effect of Surfactant and LaPlace’s Law on the Alveolus

Figure 2. Surfactant forms a thin film (blue) at the air-liquid interface within the alveoli,
lowering surface tension and therefore reducing the amount of pressure required to
maintain alveolar expansion. Adapted from “Bubbles, Babies, and Biology: The Story of
Surfactant,” by S, Wrobel, 2004, The Federation of American Societies of Experimental
Biology Journal, 18, p. 1634. Copied by permission from the Federation of American
Societies of Experimental Biology. Copyright 2016.

Pathophysiology of RDS
The characteristic abnormality in the pathophysiology of RDS is surfactant
deficiency. The observed deficiency is a direct result of lung immaturity, as surfactant
production is not adequate until about 35 weeks gestation (Davidson et al., 2012). In the
premature lung, inadequate surfactant production results in increased surface tension,
leading to instability in the alveoli at end-expiration, decreased compliance, and resultant
low lung volume (Martin, 2014b). These deficiencies in lung function in turn cause
hypoxemia due to a mismatch in ventilation and perfusion from diffuse atelectasis and
intrapulmonary and extrapulmonary shunts (Brady, 2014). Intrapulmonary shunts occur
when the blood flows through the pulmonary capillaries without participating in gas
exchange and thus is exhibited in RDS because of the damage at the ACM resulting in
the lack of oxygenation. Extrapulmonry shunting would be due to a patent ductus

EXOGENOUS SURFACTANT

14

arteriosus, which is also common in preterm neonates experiencing RDS (Davidson et al.,
2012).
Surfactant deficiency not only makes inspiration difficult but expiration as well.
If a newborn’s lungs lack surfactant, their first inhalation will cause the alveoli to
collapse during expiration due to instability of the alveoli. Some oxygen may be
absorbed initially by the alveoli, but only a fraction of the oxygen inhaled beyond the first
few breaths will be absorbed. This means that continued inspiration would require extra
effort to force air into the collapsed alveolar sacs as if every breath were just like the first.
The increased respiratory effort would tire out the newborn’s diaphragm and tear at the
lung tissues, leading to inflammation (Wrobel, 2004).
Lung inflammation and respiratory epithelial injury often accompany RDS in
neonates and may result in pulmonary edema and increased airway resistance (Martin,
2014b). Similar to the pathophysiology of acute lung injury and acute respiratory distress
syndrome in adults, RDS leads to an inflammatory response, which triggers the release of
cytokines and other cell mediators and a mass of macrophages, neutrophils, and platelets
to the damaged ACM (Perrin, 2014). The damaged capillary membrane begins to leak,
allowing protein-rich fluid to fill the collapsed alveoli, further exacerbating lung injury
and disrupting gas exchange. As capillary permeability continues to deteriorate,
neutrophils attach to the damaged membrane and may cross into the alveoli. The end
stage of this inflammatory response is the formation of hyaline membranes in the alveoli
and conduction pathways from the consolidation of proteins (Perrin, 2014).
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Clinical Manifestations and Diagnosis
The clinical manifestations of RDS primarily arise from hypoxemia due to
abnormal pulmonary function. Preterm birth is most often the cause of deficient
surfactant leading to RDS, which is why symptoms present within the first minutes to
hours after birth. If untreated, RDS progressively worsens throughout the first forty-eight
hours of life (Martin, 2014b). If neonates do not present immediately after delivery in
respiratory distress, symptoms are likely to develop within the next few hours. The
neonate will exhibit signs of respiratory distress including tachypnea, nasal flaring
(reflecting the use of accessory muscles), expiratory grunting resulting from exhalation
through a partially closed glottis, showing decreased end-expiratory volume, intercostal,
subxiphoid, and subcostal retractions due to decreased compliance and cyanosis due to
pulmonary shunting. On a physical, exam breath sounds will be decreased and pulses
diminished. Urine output is often low in these infants within the first 24-48 hours of life
and pulmonary edema is present (Martin, 2014b).
Diagnosis is often based on the clinical picture in conjunction with characteristic
chest x-ray and history of preterm birth. A chest x-ray would reveal low lung volume
and diffuse ground glass opacification resulting from atelectasis and pulmonary edema.
Other laboratory findings frequently observed in RDS include ABGs revealing
hypoxemia with an increasing partial pressure of carbon dioxide (PCO2) and
hyponatremia, which may develop as the disease progresses as a result of fluid retention
(Martin, 2014b).
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Conventional Treatment Options
Initial management of respiratory distress in neonates, regardless of etiology,
often involves supplemental oxygen therapy. Supplemental oxygen may be delivered via
facemask, continuous positive airway pressure device (CPAP), or intubation for
mechanical ventilation if progressive respiratory distress is observed. Traditionally,
noninvasive ventilation is preferred whenever possible, which makes CPAP the most
favorable option in most neonatal intensive care units. However, invasive ventilation is
often necessary for preterm neonates in respiratory distress (Brown & DiBlasi, 2011).
The goal of ventilator therapy is to prevent hypoventilation and hypoxia (Davidson et al.,
2012).
In RDS, mechanical lung expansion via CPAP or ventilator helps move the
remaining respiratory fluid out of the alveoli and into the interstitial spaces by providing
continuous positive pressure or positive end expiratory pressure (PEEP). These methods
of mechanical ventilation work to deliver much needed oxygen to the lungs and facilitate
gas exchange; however, they do not help the underlying issue of decreased surfactant
production. The goal of mechanical ventilation is to maintain oxygen saturation (SpO2)
between 90-95%, which could be measured by continuous pulse oximetry or arterial
blood gases (Davidson et al., 2012).
Appropriate fluid and metabolic provision may also be necessary treatment for
neonates with RDS; including intravenous fluids and the use of an incubator to maintain a
neutral thermal environment to decrease the neonate’s energy requirements and oxygen
consumption (Martin, 2014a). Prophylactic antibiotics may also be given to reduce the
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risk of infection or sepsis if risk factors are present. The duration of antibiotic therapy
would be determined by results of a blood culture and chest x-ray.
Another conventional treatment utilized for the prevention of RDS is antenatal
steroid therapy. The maturation effect of steroids on the fetus is the rationale behind this
treatment option. Antenatal steroids have been shown to reduce the incidence of RDS in
the low-birth-weight neonate born between 24 and 34 weeks gestation (Davidson et al.,
2012). An amniocentesis can reveal fluid from fetal lungs that can give an indication as
to the level of maturation achieved. Antenatal steroid therapy should be based on the
analysis of amniocentesis. In a controlled trial of 213 women in spontaneous premature
labor, betamethasone or a placebo was given at least twenty-four hours before delivery.
Only nine percent of babies born to treated mothers exhibited RDS symptoms, while
nearly twenty-six percent of babies born to mothers who received the placebo exhibited
symptoms (Wrobel, 2004).
Exogenous Surfactant
Production
The first clinical trials involving exogenous surfactant began in the 1980s. At this
point, scientists had made rapid advancements in physiology and biochemistry that
provided insight into the mechanisms underlying the development of RDS (Whitsett,
2014). Researchers also achieved a better understanding of the biochemical nature of the
lung and the chemical makeup of endogenous surfactant (Wrobel, 2004). Such
knowledge was instrumental in the development of both synthetic and natural exogenous
surfactant products.
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Surfactant has similar components to a cell membrane in that it is primarily made
up of proteins and phospholipids. The most abundant constituent of surfactant is the
saturated lipid, dipalmitoyl phosphatidylcholine (DPPC), which makes up about 45-70%
of endogenous surfactant (Hallman et al., 1994). DPPC acts as a stabilizing agent for a
thin film within the alveoli at the interface of liquid and air (Whitsett, 2014). This
surface film is responsible for controlling surface tension. As the lung expands, causing
tension to rise, DPPC allows the interface to stretch in response and when the lung
contracts during expiration, DPPC is responsible for packing in molecules more tightly,
thus lowering surface tension and preventing alveolar collapse (Wrobel, 2004). Based on
the knowledge of DPPC, an aerosolized form of the lipid was developed and given to
several neonates with RDS as a viable treatment option. However, DPPC alone was
shown not to be effective in eliminating symptoms entirely (Wrobel, 2004). The problem
with DPPC alone is that it does not rapidly absorb in the air-liquid interface in the alveoli,
rendering it virtually ineffective (Hallman et al., 1994).
Failure of this approach led to the investigation of the properties of other
components of surfactant, mainly unsaturated phosphatidycholine and
phosphatidylglycerol, which constitute about 25-45% of endogenous surfactant (Hallman
et al., 1994). Phosphatidylglycerol is observed in larger quantities in mature lungs than
immature lungs. Phosphatidylglycerol levels do not begin to rise in concentration until
about 35 weeks gestation, and therefore, would not be as abundant in premature neonatal
lungs. In contrast, immature lungs contain a greater amount of phosphatidylinositol than
mature lungs, which has indicated that it is a more immature form of the phospholipid
component phosphatidylglycerol (Martin, 2014b).
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Other phospholipid components of surfactant include phosphatidylethanolamine
and sphingomyelin, a saturated phospholipid with hydrophobic properties. The ratio of
lecithin (collection of previously mentioned phospholipids) to sphingomyelin (L/S) is
commonly used as an assessment tool of fetal lung maturity and is measured by
amniocentesis. An L/S ratio of two to one is ideal for a neonate at birth. Any neonate
born before a sufficient L/S ration will have varying degrees of respiratory distress
(Davidson et al., 2012).
Four other key components of endogenous surfactant are surfactant proteins A, B,
C, and D (SP-A, SP-B, SP-C, SP-D). The discovery of these proteins in endogenous
surfactant seemed to answer the question of why previously produced exogenous
surfactant containing mostly phospholipids such as DPPC were not effective
replacements. SP-B and SP-C were the first proteins to be discovered and proved to be
hydrophobic proteins that readily bind to phospholipids (Wrobel, 2004). The reason
DPPC alone was not effective as an artificial exogenous surfactant was that it could not
move rapidly enough after it was secreted to get to the air-liquid interface in the alveoli to
control surface tension. SP-B and SP-C are believed to work together to optimize a more
rapid distribution and absorption of phospholipids in exogenous surfactant, allowing for
more availability at the air-liquid interface and facilitating lower surface tension and
greater alveolar stability (Martin, 2014b).
SP-A and SP-D were more complicated structures to identify, but with
advancements in molecular biology, their significance was determined. When compared
to other identified biological proteins, SP-A and SP-D identified closely with proteins
called collectins, which aid the immune system (Wrobel, 2004). SP-A was the more
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major surfactant protein, constituting about 5% of endogenous surfactant; whereas, SP-D
was found not only in the epithelial cells of the lungs but throughout the rest of the body,
suggesting its immunologic function in the lungs may be more generalized than SP-A.
SP-A is a water-soluble protein with immunologic functions, which serves as an
innate host defense protein in the lungs (Martin, 2014b). SP-A facilitates phagocytosis of
microbes and their clearance from the airspace. Premature lungs lack SP-A, increasing a
preterm neonate’s risk for infection; however, corticosteroid therapy has shown to
increase its production. SP-A is not present in all forms of exogenous surfactant; though
its function is important, it is not critical to survival (Martin, 2014b).
There are many other minor components that make up endogenous surfactant that
have been identified, yet their significance has not yet been determined. Many
components of the antioxidant defense system, prostaglandins, growth factors, hormones,
and chemical messengers all associate with surfactant (Hallman et al., 1994). The main
components required of successful exogenous surfactant production include DPPC, SP-B,
and SP-C, which are absolutely essential. SP-A and SP-D are still considered major
components of endogenous surfactant but not entirely crucial for effective exogenous
surfactant solutions.
The two initial goals of exogenous surfactant therapy are efficacy and safety.
Other factors include minimal variation, minimal immunogenicity, sufficient resistance to
biodegradation, and availability at reasonable cost (Hallman et al., 1994). There are two
types of exogenous surfactant that may be utilized: natural and synthetic. Natural
surfactant is derived from porcine or bovine lungs through intrapulmonary lavage or by
mincing animal lung tissue and purified by lipid extraction, separating hydrophilic
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components including SP-A and SP-D (Martin, 2014c). The purified lipid preparation
contains SP-B, SP-C, DPPC, and other neutral phospholipids. Human surfactant may
also be utilized and isolated in amniotic fluid from full-term fetuses. Synthetic surfactant
combines recombinant proteins with synthetic peptides and lipids. Modified natural
surfactant may also be supplemented with phospholipid equivalents or other surfactant
components (Hallman et al., 1994). Natural surfactants tend to have a faster action of
onset and greater improvement in RDS symptoms than do synthetic derivatives. Among
the different natural surfactant derivatives there seems to be no clinically significant
differences (Martin, 2014c).
The Use and Administration of Exogenous Surfactant
Surfactant therapy is indicated for the treatment of RDS in preterm infants with
clinical symptoms. Research now suggests that the prophylactic use of surfactant be
integrated into the care of the neonate at risk for RDS (Rojas-Reyes, Morley, & Soll,
2011). Premature neonates less than 30 weeks gestation receive the most benefit from
prophylactic surfactant therapy. Exogenous surfactant therapy has significantly reduced
mortality and morbidity rates in preterm infants (Martin, 2014c). When surfactant
therapy is utilized, the following factors must be addressed:
•

Selection of surfactant preparation

•

Indications for surfactant therapy

•

Timing of administration

•

Technical aspects of administration

The types of surfactant therapy available are synthetic and natural preparations.
Both types have shown to be effective in treating RDS; however, preparations containing
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SP-B and SP-C, which were most often naturally derived surfactant, showed faster
improvement in the neonate and relief of respiratory distress. Recent research has shown
that natural preparations also contribute to lower inspired oxygen concentration (FiO2)
and ventilator pressures, a lower rate of complications from RDS, and overall decreased
mortality rate (Martin, 2014c).
Immediate stabilizing interventions are usually taken prior to the consideration of
surfactant therapy. These interventions almost always include the use of either
mechanical ventilation via endotracheal tube or the use of continuous positive airway
pressure (CPAP) shortly after birth when RDS symptoms are noted. There is data that
now suggests nasal CPAP (nCPAP) is just as effective as mechanical ventilation in
premature neonates at treating and preventing RDS complications (Martin, 2014c). Nasal
CPAP also reduces the risk of bronchopulmonary dysplasia (BPD) by avoiding
intubation. The use of nCPAP is consistent with the American Academy of Pediatrics
and the European Consensus Guidelines recommendations. Indications for intubation of
preterm neonates in severe respiratory distress or apnea include those who do not respond
to nCPAP intervention alone and require 40% or higher FiO2 to maintain an oxygen
saturation of 90%. Nasal CPAP is often initiated in the delivery room if respiratory
distress is present (Martin, 2014c). Many neonatologists will use increased levels of
PEEP and prolonged initial breaths to promote fetal lung expansion and establish
functional residual capacity (Herting, 2013).
If nCPAP intervention fails, endotracheal intubation is performed immediately,
and surfactant therapy is considered and administered once RDS diagnosis is established
and its efficacy is recognized (Martin, 2014c). If the neonate requires greater than 30%
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FiO2 an additional dose of surfactant may be required, according to most clinical research
studies (Martin, 2014c). Surfactant is traditionally administered via intratracheal
injection through a catheter inserted either through an endotracheal tube or orally
introduced to the trachea (Wrobel, 2004). When surfactant therapy is utilized, it is most
beneficial when given within the first 30-60 minutes of life. Earlier administration of
surfactant therapy has shown to have better clinical outcomes than delayed administration
including lower mortality rate and decreased risk of RDS-associated complications
including BPD, emphysema, and pneumothorax (Martin, 2014c).
During the administration of surfactant, oxygen saturation should be monitored,
as desaturation may occur. Surfactant administration may be complicated by temporary
airway obstruction caused by over insertion of the catheter in the airway or inadvertent
instillation only to the right stem bronchus (Martin, 2014c). Other possible complications
are associated with intubation and prolonged mechanical ventilation, which may cause
pulmonary injury due to volutrauma or barotrauma.
Presently, minimally invasive techniques for surfactant administration are being
considered and tested, such as less invasive surfactant administration (LISA). LISA
advocates for prophylactic administration in the delivery suite for neonates born before
27 weeks gestation. At this age, the premature fetal lung is extremely susceptible to
trauma by even short-term therapy on a mechanical ventilator; therefore, nCPAP is
utilized immediately after birth and during surfactant administration (Herting, 2013).
Close monitoring of neonate’s cardiovascular and respiratory efforts is crucial during this
procedure. If the procedure is performed beyond the first few minutes of life, peripartal
analgesia will be lost and analgesia or sedation should be considered for the neonate if
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significant discomfort is noted before attempting to introduce the catheter. Otherwise,
the majority of the time, intratracheal catheter administration is done without the use of
analgesic medication (Herting, 2013).
Dosing of surfactant administration varies among the available preparations.
Suggested dosing strategies range from 50-200mg/kg, depending on the brand and
formulation used. Several formulations are in circulation today including synthetic
formulations such as Surfaxin®, with an initial dosage of 5.8 mL/kg (DynaMed, 2016).
Other forms of surfactant include those derived from the lungs of animals such as calves,
pigs, and cows. Infasurf® is a natural surfactant derived from calf lung lavage and has an
initial dose of 105 mg/kg or 3mL/kg (DynaMed, 2016). Curosurf® is a formulation of
surfactant derived from the lungs of pigs and purified by chromatography (Hallman et al.,
1994). The initial dosage for Curosurf® is 200 mg/kg or 2.5 mL/kg (DynaMed, 2016).
Another commonly utilized animal formulation of surfactant, Alveofact® has an initial
dosage of 50 mg/kg or 1.2 mL/kg (DynaMed, 2016).
Factors such as pharmacokinetics, bioavailability, half-life and concentration in
the epithelial lining fluid (ELF) after administration serve as determinants of dosing
strategies (Herting, 2013). Type II alveolar cells are responsible for the majority of the
catabolism of exogenous surfactant. About 3-7% of the surfactant is cleared by the
airways and about 10-30% is taken up by alveolar macrophages. The type II alveolar
cells take up the remaining surfactant. In the type II alveolar cells, catabolism of
exogenous surfactant occurs in the lamellar bodies and is secreted back in to the ELF for
recycling. Recycling of exogenous surfactant incorporates the breakdown of
phospholipids in type II cells and reuses them in the synthesis of endogenous surfactant.
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Therefore exogenous surfactant increases the amount of endogenous surfactant,
contributing further to alveolar stability (Hallman et al., 1994).
Evaluation: The Impact of Exogenous Surfactant
When exogenous surfactant is administered into the airways, it obeys the
following pattern. When the surfactant is administered intratracheally, it is rapidly
distributed through the patent airways and into the airspaces. During the next one to two
hours after administration, the surfactant begins to concentrate in the lung parenchyma;
therefore, the amount of surfactant that can be lavaged from the airways decreases. From
there, the surfactant continues to congregate in the lung parenchyma and begins to flow
into the ELF where absorption occurs and recycling begins. Because surfactant is applied
directly to the airways, it does not readily diffuse into the blood stream and therefore
blood levels of the drug have little clinical importance. Only a small amount of
surfactant components may enter circulation due to high permeability and possible
pulmonary edema (Hallman et al., 1994).
In studies of exogenous surfactant administered to rabbits, maturity-dependent
differences were recognized, suggesting the same could occur in humans. In adult
rabbits, 80% of exogenous surfactant became tissue-associated within less than two hours
and about 75% of DCCP was degraded within 24 hours. In contrast, full-term newborn
rabbits exhibited about 50% tissue-association and a degradation rate of about 16%
within 24 hours. Ventilation may have increased both the degradation rate and tissueassociation rate in these animals. These conclusions suggest that a higher dosage would
be required for more developed neonates with RDS symptoms (Hallman et al., 1994).
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Other factors influencing the bioavailability of exogenous surfactant include: the
method of administration, stage and severity of pulmonary disease, and properties of
specific type of surfactant such as carrier volume and biophysical properties (Hallman et
al., 1994). Generally, about 70-90% of exogenous surfactant administered via bolusinjection through an endotracheal tube reaches the distal airways and alveoli (Dargaville,
2012). A small amount of surfactant may remain in the central airways or may be
regurgitated. Positioning the neonate on his or her right and left sides, alternating every
few minutes during and after surfactant administration, allows gravity to assist in
distribution, reducing the chances of unequal distribution within the lung fields (Hallman
et al., 1994). Additionally, repeat dosing of surfactant has been shown through numerous
clinical trials to sustain the initial response to the drug in the neonate. Giving multiple
doses of surfactant has been shown to decrease the risk of pneumothorax and other
pulmonary complications with a clearer clinical outcome expected (Soll & Ozek, 2009).
Further Research
Administration Techniques: Aerosolization
Research involving exogenous surfactant in the treatment of RDS continues
today, and focuses on aspects such as formulation, administration, and indications.
Administration methods have an impact on the amount of exogenous surfactant utilized
by the body and the accuracy of dosing strategies. Current administration techniques
include administration with the use of an aqueous carrier, as a dry powder inhalation, and
direct endotracheal injection. Administering surfactant with the aid of a saline-containing
aqueous carrier increases the volume to be distributed; however, it may have a negative
effect on pulmonary edema if it is present. Dry-powder administration of surfactant
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counteracts the adverse effects of carrier administration but poses the risk of inadequate
distribution or physical obstruction.
Under current review is the administration of surfactant through aerosolization.
Aerosolization of surfactant may be the most superior method of administration over
endotracheal bolus-instillation or carrier-mediated as far as equal distribution of the drug
is considered. However, aerosolization is associated with low bioavailability due to
inadequate synchronization of the nebulizer with inspiration of the neonate.
To solve this clinical problem, researchers incorporated the use of CPAP with
aerosolized surfactant treatment (Mazela, Merrit, & Finer, 2007). The study reported
greater improvement in oxygenation and alveolar ventilation with the use of pharyngeal
CPAP with aerosolized surfactant administration versus nCPAP delivery of aerosolized
surfactant. The reason for this discrepancy is not entirely clear and requires further
clinical trials; however, it may be attributed to the size and clearance of the nasal
passageways and dilation of airways. Regardless, aerosolization of surfactant has shown
to be more effective because of its biologic properties that enable it to distribute more
equally among the lung parenchyma (Mazela et al., 2007).
Pharyngeal Instillation
In theory, the most ideal method of delivery of exogenous surfactant would be to
instill it in the airways prior to the neonate’s first breath (Hallman et al., 1994).
Pharyngeal instillation of exogenous surfactant prior to a neonate’s first breath has been
undergoing clinical trials since the late 1990s. Pharyngeal instillation is administered
during labor before the neonate descends into the vaginal vault. Fetal lung fluid is first
suctioned from the airways and replaced with a surfactant-containing solution. By
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supplying the surfactant at the air-fluid interspace, it is presumed that the neonate will
aspirate the surfactant containing solution, allowing its distribution to the lower airways
(Abdel-Latif & Osborn, 2011). This administration technique would allow the replaced
fetal lung fluid to be the vehicle of distribution, allowing for a uniform mixing of
surfactant in the lungs and subsequent expiration of both fetal lung fluid and excess
surfactant upon initial aeration. If administered before the neonate’s first breath,
distribution would not be disturbed by hyaline membranes that form several hours to two
days after birth in a neonate with RDS, nor would there be obstructive pulmonary lesions
or edema to inhibit even distribution. This technique also avoids endotracheal intubation
and invasive mechanical ventilation, therefore reducing the risk of lung injury. The only
disadvantage of this technique is that it is difficult to accomplish and cannot be
performed in any compromised labor situation that puts the mother or neonates life at risk
(Abdel-Latif & Osborn, 2011).
Dosing Strategies
Another clinical question regarding the administration of surfactant in neonates
with RDS is whether multiple or single doses of exogenous surfactant are more beneficial
to the neonate. While a single dose of surfactant may relieve respiratory distress
symptoms initially, researchers investigated the use of multiple doses in neonates as
protocol treatment. A randomized controlled trial performed by Roger Soll and Eren
Ozek (2009) involved two groups of neonates, group one consisted of neonates with
established respiratory distress and group two consisted of neonates at high risk for
respiratory distress. In both research groups, neonates showed greater improvements in
oxygenation and ventilator requirements and a decreased risk for pneumothorax with
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trends toward improved survival. Giving multiple doses of surfactant to neonates with
RDS symptoms appears to be the most effective treatment modality as it leads to
improved clinical outcomes (Soll & Ozek, 2009).
Prophylactic Administration
Typically, the treatment for diseases such as RDS begins only after the patient
exhibits symptoms. One treatment option for neonates at high risk for RDS includes the
antenatal administration of steroids to encourage maturation of the unborn infant's
respiratory system. Another method of prophylactic treatment under current review is the
administration of exogenous surfactant prophylactically rather than selectively. The
theory behind prophylactic administration would be to treat the known cause of RDS in
neonates at high risk and thus prevent symptoms from ever occurring, thus decreasing
neonatal mortality and morbidity. The prophylactic administration of surfactant was
studied in both the term and preterm infant and reviewed by Rojas-Reyes, Morley, and
Soll through the Cochrane Neonatal Review Group. Results of the multiple reviewed
clinical trials showed significantly decreased risk of pulmonary complications associated
with RDS including pneumothorax, interstitial emphysema, bronchopulmonary dysplasia,
or death in comparison to selectively treated neonates with established RDS symptoms
(Rojas-Reyes, Morley, & Soll, 2012).
Ethical Discussion
Within the last few decades, advancements in medicine and technology have
greatly impacted the management of care of the critically ill neonate. Developments in
treatment modalities currently being incorporated into the plan of care of severely ill and
premature neonates have demonstrated an overall decrease in morbidity and mortality
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rates (Strandås & Fredriksen, 2015). The life of the critically ill infant often involves
spending months in a neonatal intensive care unit, surrounded by medical staff,
ventilators, incubators, and other medical equipment being utilized to save or prolong
their life. Unable to speak for themselves, parents are required to make decisions on the
infant’s behalf, taking into account his or her moral rights and the healthcare team’s duty
to protect.
Preterm and critically ill infants have long been the subjects of medical research
(Strandås & Fredriksen, 2015). Within the context of exogenous surfactant therapy,
ethical issues can arise concerning neonatal involvement in clinical trials of the drug
involving new administration methods, dosing strategies, and formulations. The question
of when to initiate treatment involves a rapid and complex assessment of the risk versus
benefit. The ethical principle of nonmaleficence is most often in question among these
various research studies and clinical trials as to whether their outcomes are more
concerned with the life of the neonate it involves or the efficacy of a newly developed
treatment method (Strandås & Fredriksen, 2015).
An important part of the ethical treatment of critically ill neonates lies within the
advocating powers of the nurse. The nurse’s role is to advocate for his or her patient, not
only in the everyday decisions but also often in those involving life-or-death measures. It
is the nurse’s responsibility and duty to protect their patient from mistreatment, harm, and
neglect (Strandås & Fredriksen, 2015). In the neonatal intensive care unit the nurse is
responsible for the hands-on care of the neonate. They communicate with the entire
healthcare team and work to support the parents through many tough decisions. Nurses
should be up to date on the latest medical advancements and treatment methods in order
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to effectively advocate for their patient. Ethically appropriate care should be the goal of
all treatment modalities and nursing interventions, taking into account the risks, benefit,
moral rights and duty to protect.
Conclusion
Today, thanks to much advancement in technology, knowledge, and research in
exogenous surfactant therapy, RDS is an uncommon cause of death among neonates in
developed nations. Annual death rates from RDS have decreased from 10,000-15,000
babies annually in the United States in the 1950s and 1960s to fewer than 1,000 deaths in
neonates annually (Whitsett, 2014). In the midst of incredible scientific discovery, the
story of surfactant continues to unfold with new research aiming to answer the questions
of why some babies continue to die each year from RDS, including full-term neonates,
and what other diseases exogenous surfactant therapy may be useful in treating.
Surfactant therapy, in many ways has provided the opportunity of life to babies who
otherwise may not have survived. This discovery has demonstrated a positive and
perpetual impact on past decades and will for generations to come. Surfactant therapy is
truly life saving and should be properly implemented in the neonatal care environment as
often and as appropriately as possible.
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